GlassScriptPhysician profile
Brent E Carlyle
NPI 1982960969
$11,013.45
in general payments reported to CMS, 2019-2025
49 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $1,677 · 2021: $1,432 · 2022: $1,677 · 2023: $1,903 · 2024: $1,352 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,673 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.78 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,344.69 | 2019-2025 | Speedicath, Coloplast Tfl Drive, Altis |
| Astellas Pharma US INC | $917.41 | 2019-2024 | Myrbetriq, Xtandi |
| Dendreon Pharmaceuticals LLC | $812.79 | 2019-2025 | Provenge |
| Neotract INC. | $647.69 | 2019-2020 | |
| Teleflex LLC | $599.68 | 2021-2023 | Urolift |
| Janssen Biotech, INC. | $557.71 | 2019-2025 | Erleada |
| Abbvie INC. | $437.58 | 2019-2025 | Botox |
| Medtronic, INC. | $427.94 | 2021-2025 | Interstim, Altaviva |
| Myriad Genetic Laboratories, INC. | $409.59 | 2020-2024 | Prolaris |
| Axonics, INC. | $363.88 | 2021-2024 | Bulkamid, Axonics |
| Pfizer INC. | $304.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $267.55 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.11 | 2019-2025 | |
| Caldera Medical, INC | $216.23 | 2021-2022 | |
| Urovant Sciences INC | $214.27 | 2021-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $210.59 | 2020-2024 | Jelmyto |
| Baxter Healthcare | $207.44 | 2021-2023 | Floseal, Tisseel |
| Merck Sharp & Dohme LLC | $206.94 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Accord Healthcare, INC. | $205.52 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $200.87 | 2019-2025 | Adstiladrin |
| Telix Pharmaceuticals | $196.64 | 2022-2025 | Illuccix |
| Antares Pharma, INC. | $189.29 | 2019-2024 | Xyosted |
| Boston Scientific Corporation | $184.57 | 2019-2025 | Ams 700 |
| Procept Biorobotics Corporation | $164.20 | 2024-2025 | Aquabeam System |
| Tolmar, INC. | $159.45 | 2023-2025 | Eligard, Jatenzo |
| Histosonics, INC. | $142.42 | 2025 | |
| Intuitive Surgical, INC. | $131.10 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $122.82 | 2019-2021 | |
| Olympus America INC. | $107.97 | 2023-2025 | Itind System |
| Alnylam Pharmaceuticals INC. | $96.35 | 2021-2025 | Givlaari |
| Endo Pharmaceuticals INC. | $85.13 | 2020-2023 | Xiaflex |
| Myovant Sciences INC. | $78.21 | 2021-2022 | |
| Dentsply Ih Ab | $73.24 | 2023 | Lofric |
| Sumitomo Pharma America, INC. | $57.42 | 2023-2024 | Gemtesa, Orgovyx |
| Astrazeneca Pharmaceuticals LP | $48.44 | 2021-2025 | Imfinzi |
| Endo USA, INC. | $47.74 | 2025 | Xiaflex, Aveed |
| Ethicon US, LLC | $39.94 | 2020 | |
| 180 Medical, INC. | $39.91 | 2019-2024 | Cure Ultra Catheter |
| Bard Access Systems, INC. | $39.81 | 2019 | |
| Novo Nordisk INC | $33.54 | 2025 | Rivfloza |
| Kowa Pharmaceuticals America, INC. | $30.31 | 2022 | |
| Halozyme INC | $29.14 | 2023 | |
| Medtronic USA, INC. | $23.57 | 2019 | |
| Integra Lifesciences Corporation | $19.70 | 2022 | |
| Allergan, INC. | $16.27 | 2021 | |
| Travere Therapeutics, INC. | $14.35 | 2021 | |
| Clarus Therapeutics INC. | $14.23 | 2021 | |
| Blue Earth Diagnostics | $12.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Carlyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.